Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
A prospective randomized double-blind placebo-controlled trail to investigate the effect of
high doses of IVIg on cardiac functional capacity and virus presence in a subgroup of
patients with chronic symptomatic ICM and a high PVB19 load in the heart.